Transaction DateRecipientSharesTypePriceValue
26th August 2020Lindsay A Md Rosenwald52,500Open or private purchase$18.00$945,000.00
14th July 2020Michael S Weiss16,611Grant/award etc.$0.00
14th July 2020Adam J. Chill16,611Grant/award etc.$0.00
14th July 2020Neil Herskowitz16,611Grant/award etc.$0.00
14th July 2020Lindsay A Md Rosenwald16,611Grant/award etc.$0.00
14th July 2020Michael J Zelefsky16,611Grant/award etc.$0.00
22nd June 2020Michael S Weiss1,556,029Grant/award etc.$0.00
16th June 2020Neil Herskowitz10,000Grant/award etc.$0.00
11th June 2020Manuel Md Litchman153,846Open or private purchase$3.25$499,999.50
5th June 2020Neil Herskowitz24,390Grant/award etc.$0.00
Mustang Bio
Mustang Bio logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The company was founded on March 13, 2015 and is headquartered in New York, NY.

Ticker: MBIO
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1680048
Employees: 51
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $85 M (38%)
Assets, Current: $86 M (36%)
Property, Plant and Equipment, Net: $8 M (2%)
Other Assets, Noncurrent: $250 Th (0%)
Assets: $97 M (31%)
Short-term Debt: $5 M (300%)
Accounts Payable, Current: $5 M (157%)
Liabilities, Current: $15 M (89%)
Liabilities: $26 M (18%)
Common Stock, Value, Issued: $5 Th (25%)
Common Stock, Shares, Issued: $55 M (39%)
Additional Paid in Capital, Common Stock: $223 M (29%)
Retained Earnings (Accumulated Deficit): $152 M (0%)
Stockholders' Equity (Parent): $71 M (0%)
Liabilities and Equity: $97 M (31%)
General and Administrative Expenses: $3 M (-39%)
Operating Income/Loss: $14 M (-44%)
Other Income, net: $477 Th (-41%)